Kornimate/medical-research-clean huggingface dataset:
doxycycline- and furazolidone-containing quadruple regimen is superior of tailored therapy

Conditions: Helicobacter Pylori Infection

Summary: doxycycline- and furazolidone-containing quadruple regimen can be a successful rescue treatment for helicobacter pylori infection patients after failure of several therapy. it is superior of tailored therapy as rescue treatment for helicobacter pylori infection after failure of several therapy.

this study is a prospective, multiple centers, randomized trial. patients who had failed in previous h. pylori eradication treatment that more than two times will be enrolled in sir run run shaw hospital. pretreatment h. pylori status will be defined by a positive 13 c-urea breath test (13 c-ubt). patients who had received bismuth compounds, acid inhibitor, or antibiotics during 4 weeks before 13 c-ubt are excluded. other exclusion criteria included upper gastrointestinal surgery, malignancy, and evidence of blood dyscrasia. after the patient is enrolled the patient will sign the informed consent and receive gastroscopy. more than four biopsy will be given including two in antrum and two in gastric body. one pair of biopsy sample will be sent for the pathology and the other pair is used for h.pylori culture and antibiotics sensitivity. after we get the result of antibiotics sensitivity the patient will be divided randomly into two groups, regimen a, regimen b. the regimen a includes esomeprazole (e) 20 mg, doxycycline (d) 100mg, furazolidone (f) 100 mg, and colloidal bismuth subcitrate (b) 100 mg . all drugs are taken twice a day for 14 days. the regimen b includes two antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (b) 100 mg, esomeprazole (e) 20 mg. the esomeprazole and bismuth are taken half an hour before a meal and antibiotics after the meal. all patients are asked to quit smoking and drinking and forbid eating foods rich in tyramine (e.g., chicken, cheese, pickles, lentils, beans) and seafood during and in 1 week after the treatment. patients will be followed up at the 1st day, 14th day, and 4 weeks after the treatment, respectively, and all side effects will be collected.

Eligibility criteria:
inclusion criteria: 1. a positive 13 c-urea breath test 2. formal h.pylori treatment more than two times 3. age \>18 years exclusion criteria: 1. bismuth compounds, acid inhibitor, or antibiotics during 4 weeks before the patient is enrolled 2. allergic to the medications 3. upper gastrointestinal surgery history 4. serious heart insufficiency, liver insufficiency, renal insufficiency and other serious medical problems 5. evidence of blood dyscrasia 6. pregnant and lactating women 7. can't express his complain correctly and can't cooperate with the researcher
a study of experimental medication bms-986263 in adults with advanced hepatic fibrosis after cure of hepatitis c

Conditions: Hepatic Cirrhosis; Liver Fibrosis

Summary: this is a study of experimental medication bms-986263 in adult patients with advanced hepatic fibrosis (scar tissue in the liver caused by inflammation that is far on in progress) after the patient is cured of hepatitis c (an infection caused by a virus that attacks the liver and leads to inflammation).


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * participants must provide documentation showing a sustained virologic response (svr) for at least 1 year (52 weeks) prior to the date of screening (svr is defined as a negative hepatitis c rna greater than or equal to 12 weeks from the end of therapy) * participants must have metavir stage 3 or 4 (or equivalent if using other classification; eg, ishak) exclusion criteria: * other causes of liver disease (eg, alcoholic liver disease, hbv \[serologically positive as determined using united states centers for disease control and prevention guidance for interpretation of hepatitis b serologic test results\], autoimmune hepatitis, drug-induced hepatotoxicity, wilson disease, iron overload, alpha-1-antitrypsin deficiency, nash, hemochromatosis) * participants having liver diseases associated with infection with any other hepatitis virus * detectable hcv rna at screening * child-pugh score \> 6 * model for end-stage liver disease score \>12 * evidence of hcc at screening based on alpha-fetoprotein (afp) levels: afp \> 100 ng/ml (\> 82.6 iu/ml) or afp ≥ 50 and ≤ 100 ng/ml (≥ 41.3 iu/ml and ≤ 82.6 iu/ ml) with liver ultrasound showing findings suspicious for hcc, or any imaging technique (eg, magnetic resonance imaging \[mri\] or computed tomography; based on local assessment), or ultrasound * blood transfusion in the last 6 months prior to screening due to the risk of re-infection with hcv, hbv, hiv, etc * participant has any disease or condition which, in the opinion of the investigator, might compromise patient safety (eg, hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, skeletal, central nervous system, or compliment-mediated disease); or other conditions that may interfere with the absorption, distribution, metabolism, or excretion of bms 986263, or would place the participant at increased risk other protocol defined inclusion/exclusion criteria could apply
covid-19 anxiety and phobia levels of the parents

Conditions: SARS-CoV-2; Anxiety and Fear; Parents

Summary: a pandemic that originated in the wuhan region of china in december 2019 was detected as a new type of coronavirus disease called coronavirus 2019 (covid-19). in the first phase of the outbreak, specialists explained ways to maintain physical health . however, pediatric surgical procedures and anesthesia applications continued during this period. surgery in pediatric patients is an unpleasant and potentially 'threatening' experience, often followed by preoperative anxiety due to the child's illness, hospitalization, fear of anesthesia - especially the time of anesthesia induction - and the surgery itself . anesthesia is a stressful procedure for the child and the entire family. both the covid-19 pandemic and the surgical procedure are reflected in the symptoms of anxiety, fear or acute stress disorder for children and their families. as the disease spread, investigators started to emphasize the importance of protecting mental health. identifying factors that contribute to significant preoperative anxiety levels in pediatric patients and their parents can help healthcare professionals choose the most appropriate from a variety of alternative strategies for anxiety control. this study was planned to evaluate the covid-19 anxiety and phobia levels of the parents of pediatric patients are scheduled to undergo surgery under general anesthesia in turkey.

the population of the study was created from the parents of pediatric patients who were scheduled for surgery under general anesthesia between may 2020 and september 2020 at selcuk university department of anesthesiology and reanimation. the data were obtained through face-to-face interviews before the child was taken to surgery after the necessary explanations were made to the parents of the children by the researchers. to enable the parents to answer the questions easily, a separate room in the relevant clinic was used for the interviews. the characteristics of the children and parents, supplementary data of the parents regarding the child's illness, and contact information were obtained. participants were asked to complete a sociodemographic data form, the coronavirus anxiety scale (cas), and the covid-19 phobia scale (c19p-s).

Eligibility criteria:
inclusion criteria: * parents of pediatric patients with american society of anesthesiologists classification (asa) i-ii, aged 1-12 years who were administered anesthesia to undergo surgery were included in the study. exclusion criteria: * parents of children with asa iii or higher risk, expected to have difficult intubation, serious complications related to intraoperative surgery or anesthesia (e.g. respiratory depression, myocardial depression, cardiac arrhythmia, bronchospasm, laryngospasm, anaphylactic reaction, hypotension, bleeding), and could not communicate were excluded from the study.
a prospective, observational study of individuals who seroconvert while taking truvada® for pre-exposure prophylaxis (prep)

Conditions: HIV

Summary: this study will evaluate hiv-1 rna and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of hiv-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute hiv-1 infection prior to or at the time of seroconversion.


Eligibility criteria:
inclusion criteria: * participant in a ftc/tdf prep demonstration project or ftc/tdf for prep clinical study * hiv-1 negative adults (any sex/gender, including transgender) ≥ 18 years of age at time of enrollment in the demonstration project or clinical study. * evidence of seroconversion while receiving ftc/tdf for prep exclusion criteria: * this is an observational nested study and will monitor all reported seroconversions without intervention/exclusion.

Keywords: hiv-1 truvada ftc/tdf pre-exposure prophylaxis prep resistance
caffeinated chewing gum on special forces performance

Conditions: Caffeine; Placebo

Summary: the purpose of this project is to investigate the effects of caffeine chewing gum on the cognitive functions and special operations capabilities of special forces.

using a randomisation crossover design, 20-40 active-duty special forces members who had undergone leave and special forces reserve training were divided into a caffeine trial (caf) and a placebo trail (pl). after chewing caffeine-containing gum containing 5 mg/kg (caf group) or caffeine-free gum (pl group) for 15 minutes, then performed a simple reaction test, a stroop test, a visual search test, a grip strength test, a vertical jump test, a 20-metre sprint test, and a counter-terrorism simulation test. a heart rate monitor was used to measure the heart rate and heart rate variability of the participants. saliva samples were collected and analysed for α-amylase, cortisol and caffeine concentrations before the test, after a 15-minute break from chewing gum and at the end of the test. completion time of cognitive functions, grip strength, vertical jump height, 20 m sprint time, time to completion of the counterterrorism simulation test, and target score will be analysed using paired-sample t-tests.

Eligibility criteria:
inclusion criteria: * active special warfare unit members who have passed the grade a special forces reserve training * no cardiovascular and joint diseases * adult male over 20 years old exclusion criteria: * non-active special warfare unit members * have cardiovascular and joint diseases * under age

Keywords: exercise performance
using ar dental care training system in he on periodontal status, blood sugar control and qol in patients with t2dm

Conditions: Diabetes Mellitus Type 2 With Periodontal Disease

Summary: the aim of this study was to evaluate the long-term effectiveness of an ar dental care training in health education on periodontal status, blood sugar control and quality of life in patients with poorly controlled type 2 diabetes. this randomized controlled trial included experimental group: ar group (eg-a), ar-health consulting group (eg-b) and control group (cg), respectively. the eg-a and eg-b received ar dental care training intervention 2 to 3 times during non-surgical periodontal treatment. baseline and follow-up surveys were used to collect the data in periodontal index, blood sugar data, oral health knowledge, attitudes, behavior, oral health-related quality of life.

a randomized experimental design was used. patients with type 2 diabetes whose aged 35-65 years and hba1c over 7% in the past six months were recruited through department of endocrinology and metabolism in kaohsiung medical university hospital. each group was expected for 100 per group, patients will be randomized into each group. g\*power (version 3.1.9.4) was used for power analysis. all patients will underwent periodontal examination at baseline and at 1-month, 3-month, 6-month and 1 year follow-ups. each patients will be diagnosed periodontal disease by dentist and have more than 12 functional teeth. each patients will completed the questionnaire at baseline and at 1-month, 3- month,6-month and 1 year follow-up.

Eligibility criteria:
inclusion criteria: * age 35 years old (inclusive) and above * hba1c over 7% in the past six months * there are more than 12 functional teeth to ensure that the patient has enough teeth to evaluate the periodontal condition exclusion criteria: * have received periodontal treatment within the previous 6 months * habits of smoking, drugs and betel nut chewing * taking antibiotics and osteoporosis bisphosphonates and other drugs regularly * people with cognitive function or physical and mental disabilities * severely impaired diseases (for example: cancer, renal function or liver failure, etc.)

Keywords: augmented reality periodontitis blood sugar control type 2 diabetes
total hip arthroplasty compared to internal fixation for displaced intracapsular fractures of the femoral neck

Conditions: Femoral Neck Fracture

Summary: the primary aim of this study was to determine the harris hip score as an evaluation of hip function, in mentally competent elderly patients (\>65 years old) treated with either thr or if, after contracting a displaced femoral neck fracture. the secondary aim was to compare the rate of reoperations and complications between the two groups.


Eligibility criteria:
inclusion criteria: * acute displaced femoral neck fracture garden iii or iv, * age over 65 years, * admission from their own home, * no concurrent joint disease or previous fracture in the lower extremities, * healthy or controlled medical conditions without significant systemic effects (asa 1-2), * harris hip score of 100 * acceptance from the patient to participate in the study.

Keywords: femoral neck fracture total hip arthroplasty internal fixation
efficacy and safety of oms103hp in patients undergoing autograft anterior cruciate ligament (acl) reconstruction

Conditions: Knee Injuries

Summary: the anterior cruciate ligament (acl) is an important stabilizer of the knee. orthopedic surgeons replace the torn ligament during acl reconstruction surgery. surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. oms103hp was designed to deliver targeted therapeutic agents directly to the surgical site during the arthroscopic procedure to inhibit inflammation and pain before they can begin. the purpose of this study is to assess the effectiveness and safety of oms103hp in improving knee function following acl reconstruction using a hamstring autograft. secondary benefits being evaluated include reduced postoperative pain, improvement in knee range of motion, and earlier return to work.


Eligibility criteria:
inclusion criteria: * 15 - 65 years of age * in good general health with an acl tear that occurred from 2 weeks to 18 months prior to the day of arthroscopic surgery * undergoing primary unilateral acl reconstruction using a medial hamstring (semitendinosus and gracilis) autograft * able to participate in the study rehabilitation protocol * and other inclusion criteria exclusion criteria: * allergies to any of the individual ingredients in oms103hp * taking medications with the same activities as that of the active ingredients in oms103hp for defined time intervals prior to and after surgery * associated knee injuries likely to interfere with evaluation of the study drug * and other exclusion criteria

Keywords: anterior cruciate ligament reconstruction acl reconstruction
serum level measurement of oral paracetamol and oral ibuprofen for patent ductus arteriosus treatment in preterm infants

Conditions: Patent Ductus Arteriosus

Summary: the purpose of this study is to determine oral paracetamol and ibuprofen efficacy and safety in relation to serum levels in closure of patent ductus arteriosus in preterm infants.

to determine oral paracetamol and ibuprofen efficacy and safety in relation to serum levels in closure of patent ductus arteriosus in preterm infants. eighty preterm infants with patent ductus arteriosus will be enrolled in this prospective-randomized study. patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h or oral paracetamol 15 mg/kg per dose every 6 hours for 3 days. one of the following echocardiographic criteria of a duct size \> 1.5 mm, a left atrium-to-aorta ratio \> 1.5, left-to-right shunting of blood, end diastolic reversal of blood flow in the aorta, or poor cardiac function in addition signs of patent ductus arteriosis determined the need of treatment. three consecutive blood sample from infants for 3 days before dose application of drugs(ibuprofen and paracetamol will be obtained. the relation of pharmacokinetics of drugs to drug response will be evaluated

Eligibility criteria:
inclusion criteria: * birth weight below 1250 gram * diagnosed patent ductus arteriosus by echocardiographic examination exclusion criteria: * accompanied other congenital cardiac anomalies * severe thrombocytopenia \< 60.000 * severe intracranial bleeding (grade iii - iv) * intestinal abnormality and necrotising enterocolitis

Keywords: patent ductus arteriosus paracetamol ibuprofen serum levels preterm infant
physical function, health and employment for people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: employment is low in people with ms, even when physical levels of functioning are high. the purpose of this study is to investigate if an individually tailored intervention combining individualized physiotherapy and work adaptation works better than usual care in terms of reducing barriers for work and improving levels of physical activity. the utility of the intervention will be investigated in terms of quality adjusted life years, long-term employment status and work-related costs.

physiotherapy and physical activity interventions can reduce fatigue, improve balance, walking, hrqol, and may improve neuromuscular and physical functioning in people with ms. however, these interventions lack coordination between health care levels and sectors and rarely address vital employment adaptations. optimizing function and physical activity, when disability is low and neuroplasticity is optimal, can be valuable for maintaining work as levels of fatigue, mobility related symptoms and cognitive disturbances are associated with current employment. people with an ms-diagnosis who reside in the north of norway will be identified from patient lists from the neurological out-patient clinics in the participating hospitals. upon the provision of written informed consent, all participants will undergo baseline testing prior to randomization into either the intervention or the control group. the intervention group will receive a physiotherapy assessment at the hospitals focusing on opportunities for change. following this assessment they will participate in group training with a municipality physiotherapist twice weekly for six weeks followed by independent training for six weeks. in addition, both participants and their employers will get access to information films on opportunities for work adaptations and the importance of physical activity. structured meetings with a specially trained employment consultant, the participant and their employer will be held to discuss possible work adaptations. goals will be set and formally evaluated. retests will be carried out at week 9, 16 and 52. registry data on employment will be obtained from the norwegian labour and welfare administration as a part of a cost-benefit analysis of the intervention.

Eligibility criteria:
inclusion criteria: * diagnosed with multiple sclerosis according to the mcdonald's criteria * extended disability status scale (edss) 0-4 * being employed, part time or full time, may include various degrees of sick leave, disability pension or aap. * living in the participating 18 municipalities (hammerfest, alta, senja, målselv, tromsø, harstad, narvik, fauske, bodø, meløy, vågan, vestvågøy, sortland, hadsel, rana, vefsn, alstadhaug, brønnøy). exclusion criteria: * pregnancy at enrolment. * exacerbation of symptoms (i.e. relapse) within two weeks prior to enrolment. * other serious conditions.

Keywords: physiotherapy employment physical activity health related quality of life cost-benefit
odansetron and dexamethasone alone vs. odansetron, dexamethason and apreptant to prevent nausea

Conditions: Nausea; Vomiting

Summary: the purpose of this study is to compare two different treatment protocols for treating nausea and vomiting in patients who have undergone bone marrow transplant. patients will be assigned to one of two treatment groups. the first group will recieve ondansetron (zofran) tablets combined with a medicine called dexamethasone given iv. both of these drugs are commercially available. patients in the second treatment consists of the first two drugs, plus a newly approved drug known as aprepitant (mk-869, emend). this combination will be the treatment being tested. the combination is approved by the fda for chemotherapy regimens known to cause a lot of nausea and vomiting. it significantly decreases the delayed (more than 24 hours after therapy) nausea and vomiting seen with these regimens.

this will be a single center, comparative, randomized, double-blind, phase iii trial designed to evaluate the efficacy of the nk-1 antagonist, aprepitant (mk-869), in combination with ondansetron and dexamethasone in the prevention of acute and delayed nausea and vomiting compared to ondansetron and dexamethasone in patients receiving highly emetogenic preparative regimens prior to autologous or allogeneic (related and unrelated) stem cell transplantation. patients will be randomized to one of two treatments: dexamethasone 10 mg iv once daily and ondansetron 8 mg orally every 8 hours on each day of the preparative regimen plus one additional day vs. 7.5 mg iv once daily and ondansetron 8 mg orally every 8 hours on each day of the preparative regimen plus one additional day combined with aprepitant, 125 mg orally on the first day of their preparative regimen followed by 80 mg daily on each remaining day of the preparative regimen plus three additional days.

Eligibility criteria:
inclusion criteria: * diagnosis of cancer, admitted for myelosupppresive stem cell transplantation. included preparative regimens include: tbi/vp16/cy, tbi/cy, bu/cy (po \& iv), and bcv * age 18 or older * alcohol intake \<100 gm/d for the last year (\< approximately 5 drinks per day) * renal function: estimated or measured crcl 50 ml/min * liver function: t.bili \<1.5, ast \< 2x uln, unless due to disease * able to swallow tablets and capsules exclusion criteria: * age \< 18 * high alcohol intake \[\> 100 gm/d in the last year\] * allergy or intolerance to: ondansetron or dexamethasone * renal dysfunction \[measured or estimated crcl \< 50 ml/min\] * liver dysfunction \[t.bili \> 1.5, ast \> 2x uln, unless due to disease\] * inability to swallow tablets or capsules * concurrent condition requiring systemic steroid use * nonmyeloablative sct, patients receiving the conditioning regimens not included \[see inclusion criteria\] * history of anticipatory nausea and vomiting

Keywords: bone marrow transplant nausea vomiting nk-1 antagonist